RT期刊文章SR电子T1肺癌的系统和联合内膜术分期（得分研究）JF欧洲呼吸杂志JO EUR RESSIR J FD欧洲呼吸协会SP 1800800 DO 10.1183/13993003.00800-2018 VO 53 IS188bet官网地址A1 DOMS，Christophe A1 Stigt，Jos A. A1 Tournoy，Kurt G.A1 Schuelbiers，Olga C.J. A1 Ninaber，Maarten K. A1 Buikhuisen，Wieneke A. A1 Hashemi，Sayed M.S.A1 Bonta，Peter I. A1 Korevaar，DaniëlA。A1 Anema，Jouke T. YR 2019 UL //www.qdcxjkg.com/content.com/content/53/2/2/1800800.ABSTRACS AB TRACS ABSTRESS ABSTRESS ABSTRACS PUIDELINES PURESSTARME在患者的媒介节结节nodal exting tage in decullines trupe可切除的非小细胞肺癌（NSCLC）。我们假设使用相同的EBUS支气管镜（EUS-B）进行了系统的支架超声（EBUS）评估以及食管研究，可以改善纵隔节点分期，而不是当前的有针对性正电子发射层摄影（PET）的实践实践。仅EBUS分阶段。PET-CT后，患者接受了系统的EBU和EUS-B。对CT，PET，EBUS和/或EUS-B成像以及第4R，4L和7（短轴≥8mm）的节点进行了可疑。对于在内部射照学确定的没有N2/N3疾病的患者中，手术病理分期是参考标准。N2/N3疾病的患病率为229例患者（45％）。 A PET-CT-guided targeted approach by EBUS identified 75 patients with N2/N3 disease (sensitivity 73%, 95% CI 63–81%; negative predictive value (NPV) 81%, 95% CI 74–87%). Four additional patients with N2/N3 disease were found by systematic EBUS (sensitivity 77%, 95% CI 67–84%; NPV 84%, 95% CI 76–89%) and five more by EUS-B (84 patients total; sensitivity 82%, 95% CI 72–88%; NPV 87%, 95% CI 80–91%). Additional clinical relevant staging information was obtained in 23 out of 229 patients (10%).Systematic EBUS followed by EUS-B increased sensitivity for the detection of N2/N3 disease by 9% compared to PET-CT-targeted EBUS alone.In lung cancer patients, a systematic endobronchial ultrasound (EBUS) combined with an oesophageal investigation using the same EBUS bronchoscope (EUS-B) increases the sensitivity for mediastinal nodal staging by 9% compared to a targeted EBUS procedure http://ow.ly/aPqF30mJ15q